Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Thalidomide × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precancerous Conditions 1 Neoplasms, Plasma Cell 1 Medulloblastoma 1 Mastocytosis, Systemic 1 Lymphoma, Mantle-Cell 1 Liver Neoplasms 1 Leukemia, Large Granular Lymphocytic 1 Ependymoma 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 38 Dexamethasone 31 venetoclax 28 fludarabine 27 pembrolizumab 20 pomalidomide 17 Rituximab 17 Gemcitabine 16 Lenalidomide 14 Cytarabine 14 carfilzomib 11 Nivolumab 11 fludarabine phosphate 10 Temozolomide 10 Etoposide 10 Calcium Dobesilate 10 Azacitidine 10 glofitamab 9 daratumumab 9 Injections 9 obinutuzumab 8 Cisplatin 8 ibrutinib 7 cemiplimab 7 Carboplatin 7 Capecitabine 7 Bevacizumab 7 zanubrutinib 6 selinexor 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡